Product Description
SynKIR™-310 relies on Verismo's unique KIR-CAR platform and proprietary CD19 binder (DS191). The binder was developed specifically for the KIR-CAR platform technology to enable treatment of B-cell associated disorders and malignancies. SynKIR™-310 is directed by DS191 to target a similar epitope of CD19 as the commercially approved CAR T therapies, with the added potential to prolong the anti-tumor T cell function and persistence. Verismo's co-founders Dr. Donald Siegel and Dr. Michael Milone are co-inventors of the binder. (Sourced from: https://www.prnewswire.com/news-releases/verismo-therapeutics-receives-ind-clearance-from-the-fda-for-synkir-310-in-relapsedrefractory-b-cell-nhl-302144410.html)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Verismo Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|